Loading...

Neal Swerdlow

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentPsychiatry
Address9500 Gilman Drive #0804
La Jolla CA 92093
Phone619-543-6270
vCardDownload vCard

    Collapse Overview 
    Collapse Overview

    Biography

    Neal Swerdlow, M.D., Ph.D. is Professor of Psychiatry, Director of the Research Residency Track and Vice Chair of Education and Training in the Department of Psychiatry at the University of California, San Diego, School of Medicine. Dr. Swerdlow graduated Summa Cum Laude, Phi Beta Kappa, from Amherst College (Neuroscience) in 1981, received his M.D. and Ph.D. (Neuroscience) from UCSD in 1986, completed the UCSD Psychiatry Residency Program and joined the faculty of the Department of Psychiatry in 1991. Since that time, he has been continuously NIH-funded, was Director of the Psychiatry Core Clerkship for 17 years, and directed separate clinical programs in the treatment of Obsessive Compulsive Disorder (OCD), Tourette Syndrome (TS) and Huntington's Disease (HD).

    Research Interests

    Dr. Swerdlow has published over 250 peer-reviewed research papers, 35 chapters and 1 book. His laboratories study the neural regulation of information processing and its deficiencies in schizophrenia, TS and OCD, and have been home to many dozens of students, from undergraduates to Fellows. Dr. Swerdlow’s career has focused heavily on service to our field and patients. For 10 years, he chaired the Tourette Syndrome Association Scientific Advisory Board, he served the San Diego NAMI for 10 years as a member of their Board of Directors and Chair of their Medical Advisory Board, has been a Program Chair for the American College of Neuropsychopharmacology, chaired and sat on many NIH review committees, was Associate Editor of Behavioral Neuroscience and Editorial Board member of several high-impact journals in our field. Neal is a past recipient of the APA Award for Research in Psychiatry, the ACNP Joel Elkes Award, APA Kempf Award, NAMI Judith Silver Award, TSA Champion of Children's Award, and ACP Laughlin Fellowship, among other awards.


    Collapse Research 
    Collapse Research Activities and Funding
    Psychiatric Research Residency Training Track
    NIH/NIMH R25MH101072Jul 1, 2013 - Jun 30, 2023
    Role: Principal Investigator
    Memantine effects on sensorimotor gating and neurocognition in schizophrenia
    NIH/NIMH R01MH094320Jun 8, 2012 - Mar 31, 2021
    Role: Principal Investigator
    Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
    NIH/NIMH R34MH093453Jul 1, 2011 - Mar 31, 2014
    Role: Principal Investigator
    Genetics of individual differences in amphetamine effects on startle gating
    NIH/NIDA R03DA027483Sep 1, 2009 - Aug 30, 2011
    Role: Principal Investigator
    Neuroscience at the Boundaries of Neurology and Psychiatry
    NIH/NIMH R25MH076768Sep 30, 2005 - Aug 31, 2008
    Role: Principal Investigator
    Psychiatric Research Residency Training Track
    NIH/NIMH R25MH074508Jul 27, 2005 - Jun 30, 2010
    Role: Principal Investigator
    A Simple Measure for Studying Sensory Gating Deficits
    NIH/NIMH R01MH069589Jul 1, 2004 - Jun 30, 2009
    Role: Principal Investigator
    Neural Basis of Heritable DA-Mediated Gating Deficits
    NIH/NIMH R01MH068366Jul 15, 2003 - Jun 30, 2011
    Role: Principal Investigator
    Pharmacologic augmentation of neurocognition and cognitive training in psychosis
    NIH/NIMH R01MH059803May 1, 1999 - May 31, 2019
    Role: Principal Investigator
    III INTERNATIONAL SYMPOSIUM ON TOURETTE SYNDROME
    NIH/NINDS R13NS038340Sep 25, 1998 - Aug 31, 1999
    Role: Principal Investigator
    Neural Circuitry of Sensorimotor Gating Across Species
    NIH/NIMH K02MH001436Feb 1, 1997 - Jan 31, 2007
    Role: Principal Investigator
    Cortico-Striatal Substrates of Deficient Startle Gating
    NIH/NIMH R01MH053484Jan 15, 1997 - Dec 31, 2010
    Role: Principal Investigator
    SEX DIFFERENCES IN SENSORIMOTOR MODULATION
    NIH/NIMH R03MH054621Aug 1, 1996 - Jul 31, 1998
    Role: Principal Investigator
    STRIATO-PALLIDAL SUBSTRATES OF DEFICIENT STARTLE GATING
    NIH/NIMH R29MH048381Sep 30, 1992 - Aug 31, 1997
    Role: Principal Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Thomas ML, Bismark AW, Joshi YB, Tarasenko M, Treichler EBH, Hochberger WC, Zhang W, Nungaray J, Sprock J, Cardoso L, Tiernan K, Attarha M, Braff DL, Vinogradov S, Swerdlow N, Light GA. Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. Schizophr Res. 2018 Jul 25. PMID: 30055883.
      View in: PubMed
    2. Swerdlow NR, Bhakta SG, Light GA. Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge. Schizophr Res. 2018 Apr 04. PMID: 29627173.
      View in: PubMed
    3. Swerdlow NR, Light GA. Sensorimotor gating deficits in schizophrenia: Advancing our understanding of the phenotype, its neural circuitry and genetic substrates. Schizophr Res. 2018 Mar 07. PMID: 29525460.
      View in: PubMed
    4. Kantrowitz JT, Swerdlow NR, Dunn W, Vinogradov S. Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Feb 22. PMID: 29656951.
      View in: PubMed
    5. Bhakta SG, Light GA, Talledo JA, Balvaneda B, Hughes E, Alvarez A, Rana BK, Young JW, Swerdlow NR. Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors. Int J Neuropsychopharmacol. 2017 12 01; 20(12):979-987. PMID: 29020372.
      View in: PubMed
    6. Swerdlow NR, Bhakta SG, Talledo JA, Franz DM, Hughes EL, Rana BK, Light GA. Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients. Neuropsychopharmacology. 2018 Mar; 43(4):708-717. PMID: 29154367.
      View in: PubMed
    7. Swerdlow NR, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, Rana B, Vinogradov S, Light GA. Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. Schizophr Bull. 2017 Jul 01; 43(4):872-880. PMID: 27798224.
      View in: PubMed
    8. Swerdlow NR, Light GA, Thomas ML, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophr Res. 2017 May 23. PMID: 28549722.
      View in: PubMed
    9. Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow NR. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia. Neuropsychopharmacology. 2017 Dec; 42(13):2633-2639. PMID: 28425497.
      View in: PubMed
    10. Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, Swerdlow NR, Light GA. Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. Neuropsychopharmacology. 2017 Oct; 42(11):2206-2213. PMID: 28139679.
      View in: PubMed
    11. Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Shiluk AL, Siever LJ, Silverman JM, Sprock J, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Light GA. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. JAMA Psychiatry. 2017 Jan 01; 74(1):37-46. PMID: 27926742.
      View in: PubMed
    12. Swerdlow NR, Bhakta SG, Rana BK, Kei J, Chou HH, Talledo JA. Sensorimotor gating in healthy adults tested over a 15 year period. Biol Psychol. 2017 02; 123:177-186. PMID: 28027936.
      View in: PubMed
    13. Swerdlow NR, Braff DL, Geyer MA. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 2016 11; 30(11):1072-1081. PMID: 27539931.
      View in: PubMed
    14. Cope ZA, Halberstadt AL, van Enkhuizen J, Flynn AD, Breier M, Swerdlow NR, Geyer MA, Young JW. Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology (Berl). 2016 10; 233(19-20):3513-25. PMID: 27534540.
      View in: PubMed
    15. Downs NS, Alderman T, Schneiber K, Swerdlow NR. Treat and Teach Our Students Well: College Mental Health and Collaborative Campus Communities. Psychiatr Serv. 2016 Sep 01; 67(9):957-63. PMID: 27181737.
      View in: PubMed
    16. Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow NR, Tsuang M, Turetsky B, Radant A, Tsuang DW. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 07; 174(1-3):1-9. PMID: 27132484; PMCID: PMC4912929 [Available on 07/01/17].
    17. Bhakta SG, Chou HH, Rana B, Talledo JA, Balvaneda B, Gaddis L, Light GA, Swerdlow NR. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. Psychopharmacology (Berl). 2016 06; 233(12):2399-410. PMID: 27076209.
      View in: PubMed
    18. Tarasenko M, Perez VB, Pianka ST, Vinogradov S, Braff DL, Swerdlow NR, Light GA. Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. Schizophr Res. 2016 Apr; 172(1-3):123-30. PMID: 26851143.
      View in: PubMed
    19. Swerdlow CD, Blumenthal T, Swerdlow NR. Reawakening research on reducing shock pain. Heart Rhythm. 2016 05; 13(5):1149-50. PMID: 26795457.
      View in: PubMed
    20. Swerdlow NR, Light GA. Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant? Curr Top Behav Neurosci. 2016; 28:305-25. PMID: 27311762.
      View in: PubMed
    21. Amitai N, Powell S, Weber M, Swerdlow NR, Young JW. Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine. Cogn Affect Behav Neurosci. 2015 Dec; 15(4):901-14. PMID: 26220402; PMCID: PMC4641795 [Available on 12/01/16].
    22. Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res. 2016 Jan; 170(1):30-40. PMID: 26597662; PMCID: PMC4707095 [Available on 01/01/17].
    23. Greenwood TA, Light GA, Swerdlow NR, Calkins ME, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. Am J Psychiatry. 2016 Apr 01; 173(4):385-91. PMID: 26441157; PMCID: PMC4933520 [Available on 04/01/17].
    24. Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis. Neuropsychopharmacology. 2016 Jan; 41(2):419-30. PMID: 26062785.
      View in: PubMed
    25. Light GA, Swerdlow NR. Bending the curve on psychosis outcomes. Lancet Psychiatry. 2015 May; 2(5):365-367. PMID: 26360262.
      View in: PubMed
    26. Gur RC, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophr Res. 2015 Apr; 163(1-3):17-23. PMID: 25432636; PMCID: PMC4441547.
    27. Light GA, Swerdlow NR. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 2015 May; 1344:105-19. PMID: 25752648; PMCID: PMC4412775.
    28. Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):38-46. PMID: 25749017; PMCID: PMC4382444.
    29. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Factor structure and heritability of endophenotypes in schizophrenia: findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. PMID: 25682549.
      View in: PubMed
    30. Radant AD, Millard SP, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Meichle SP, Nuechterlein KH, Olincy A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Sugar CA, Tsuang MT, Turetsky BI, Tsuang DW. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophr Res. 2015 Apr; 163(1-3):47-52. PMID: 25553977; PMCID: PMC4382408.
    31. Stone WS, Mesholam-Gately RI, Braff DL, Calkins ME, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ. California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):32-7. PMID: 25497440.
      View in: PubMed
    32. Swerdlow NR, Gur RE, Braff DL. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this Special Issue of Schizophrenia Research. Schizophr Res. 2015 Apr; 163(1-3):9-16. PMID: 25454799; PMCID: PMC4382419.
    33. Light GA, Swerdlow NR, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff DL, Turetsky BI. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):63-72. PMID: 25449710; PMCID: PMC4382452.
    34. Tarasenko MA, Swerdlow NR, Makeig S, Braff DL, Light GA. The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis. Front Psychiatry. 2014; 5:142. PMID: 25352811; PMCID: PMC4195270.
    35. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Light G. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):53-62. PMID: 25306203; PMCID: PMC4382423.
    36. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications. Schizophr Res. 2015 Apr; 163(1-3):24-31. PMID: 25248939; PMCID: PMC4368500.
    37. Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr Bull. 2014 Nov; 40(6):1404-11. PMID: 24903414; PMCID: PMC4193725.
    38. Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff DL, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. PMID: 24913833; PMCID: PMC4110721.
    39. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B, Radant A. Is there an association between advanced paternal age and endophenotype deficit levels in schizophrenia? PLoS One. 2014; 9(2):e88379. PMID: 24523888; PMCID: PMC3921166.
    40. Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014 Feb; 152(2-3):503-12. PMID: 24405980; PMCID: PMC3960985.
    41. Perez VB, Swerdlow NR, Braff DL, Näätänen R, Light GA. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med. 2014; 8(1):9-14. PMID: 24325220; PMCID: PMC4043396.
    42. Light GA, Swerdlow NR. Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle. Curr Top Behav Neurosci. 2014; 21:293-314. PMID: 24850080.
      View in: PubMed
    43. Swerdlow NR, Light GA, Trim RS, Breier MR, Hines SR, Powell SB. Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. Behav Brain Res. 2013 Nov 15; 257:118-28. PMID: 24076151; PMCID: PMC3897308.
    44. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013 Aug 01; 154(3):518-29. PMID: 23911319; PMCID: PMC3894107.
    45. Swerdlow NR, Powell SB, Breier MR, Hines SR, Light GA. Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats. Neuropharmacology. 2013 Dec; 75:38-46. PMID: 23810830; PMCID: PMC3825835.
    46. Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff DL. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May; 170(5):521-32. PMID: 23511790; PMCID: PMC3878873.
    47. Swerdlow NR, Hines SR, Herrera SD, Weber M, Breier MR. Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains. Pharmacol Biochem Behav. 2013 May; 106:128-31. PMID: 23567203; PMCID: PMC3760336.
    48. Calkins ME, Ray A, Gur RC, Freedman R, Green MF, Greenwood TA, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Lazzeroni LC, Gur RE. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biol Psychiatry. 2013 May 15; 73(10):976-84. PMID: 23395246; PMCID: PMC3954126.
    49. Chou HH, Talledo JA, Lamb SN, Thompson WK, Swerdlow NR. Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults. Psychopharmacology (Berl). 2013 May; 227(1):165-76. PMID: 23314393; PMCID: PMC3624060.
    50. Swerdlow NR. Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome. Neurosci Biobehav Rev. 2013 Jul; 37(6):1150-6. PMID: 23017868; PMCID: PMC3566359.
    51. Amitai N, Weber M, Swerdlow NR, Sharp RF, Breier MR, Halberstadt AL, Young JW. A novel visuospatial priming task for rats with relevance to Tourette syndrome and modulation of dopamine levels. Neurosci Biobehav Rev. 2013 Jul; 37(6):1139-49. PMID: 23010529; PMCID: PMC3556379.
    52. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer MA, Braff DL. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. PMID: 22802938.
      View in: PubMed
    53. Swerdlow NR, Shilling PD, Breier M, Trim RS, Light GA, Marie RS. Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology (Berl). 2012 Dec; 224(3):349-62. PMID: 22700037.
      View in: PubMed
    54. Rissling AJ, Braff DL, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, Pela M, Light GA. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012 Oct; 123(10):1942-9. PMID: 22608970; PMCID: PMC3436955.
    55. Swerdlow NR, Light GA, Breier MR, Shoemaker JM, Saint Marie RL, Neary AC, Geyer MA, Stevens KE, Powell SB. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev Neurosci. 2012; 34(2-3):240-9. PMID: 22572564.
      View in: PubMed
    56. Kirihara K, Rissling AJ, Swerdlow NR, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):873-80. PMID: 22361076.
      View in: PubMed
    57. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One. 2012; 7(1):e29630. PMID: 22253750; PMCID: PMC3258248.
    58. Swerdlow NR. Beyond antipsychotics: pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia. Neuropsychopharmacology. 2012 Jan; 37(1):310-1. PMID: 22157876; PMCID: PMC3238077.
    59. Chou HH, Twamley E, Swerdlow NR. Towards medication-enhancement of cognitive interventions in schizophrenia. Handb Exp Pharmacol. 2012; (213):81-111. PMID: 23027413; PMCID: PMC3629915.
    60. Chang WL, Weber M, Breier MR, Saint Marie RL, Hines SR, Swerdlow NR. Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Res. 2012 Feb 09; 1437:69-76. PMID: 22227455; PMCID: PMC3268831.
    61. Chang WL, Breier MR, Yang A, Swerdlow NR. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats. Pharmacol Biochem Behav. 2011 Oct; 99(4):634-8. PMID: 21683731.
      View in: PubMed
    62. Swerdlow NR. Are we studying and treating schizophrenia correctly? Schizophr Res. 2011 Aug; 130(1-3):1-10. PMID: 21645998; PMCID: PMC3139794.
    63. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. PMID: 21498463; PMCID: PMC3751972.
    64. Sutherland Owens AN, Miguel EC, Swerdlow NR. Sensory gating scales and premonitory urges in Tourette syndrome. ScientificWorldJournal. 2011 Mar 22; 11:736-41. PMID: 21442151.
      View in: PubMed
    65. Swerdlow NR, Breier MR, Saint Marie RL. Probing the molecular basis for an inherited sensitivity to the startle-gating disruptive effects of apomorphine in rats. Psychopharmacology (Berl). 2011 Aug; 216(3):401-10. PMID: 21365203.
      View in: PubMed
    66. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. PMID: 21288694.
      View in: PubMed
    67. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff DL. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Curr Protoc Neurosci. 2010 Jul; Chapter 6:Unit 6.25.1-24. PMID: 20578033.
      View in: PubMed
    68. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. PMID: 20382002; PMCID: PMC3688282.
    69. Chang WL, Swerdlow NR, Breier MR, Thangaraj N, Weber M. Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats. Pharmacol Biochem Behav. 2010 Jun; 95(4):473-8. PMID: 20385162; PMCID: PMC2889248.
    70. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. PMID: 20374545; PMCID: PMC4176871.
    71. Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR. The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats. Eur Neuropsychopharmacol. 2010 Jun; 20(6):421-5. PMID: 20346635; PMCID: PMC2864324.
    72. Chang WL, Geyer MA, Buell MR, Weber M, Swerdlow NR. The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behav Pharmacol. 2010 Mar; 21(2):135-43. PMID: 20215963; PMCID: PMC2890261.
    73. Breier MR, Lewis B, Shoemaker JM, Light GA, Swerdlow NR. Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats. Behav Brain Res. 2010 Apr 02; 208(2):560-5. PMID: 20080128; PMCID: PMC2834557.
    74. Swerdlow NR. Integrative circuit models and their implications for the pathophysiologies and treatments of the schizophrenias. Curr Top Behav Neurosci. 2010; 4:555-83. PMID: 21312413.
      View in: PubMed
    75. Swerdlow NR (Ed.).. Behavioral Neurobiology of Schizophrenia and Its Treatment. 2010; 1-657.
    76. Swerdlow NR. Behavioral neurobiology of schizophrenia and its treatment. Preface. Curr Top Behav Neurosci. 2010; 4:v-vii. PMID: 21312394.
      View in: PubMed
    77. Qu Y, Saint Marie RL, Breier MR, Ko D, Stouffer D, Parsons LH, Swerdlow NR. Neural basis for a heritable phenotype: differences in the effects of apomorphine on startle gating and ventral pallidal GABA efflux in male Sprague-Dawley and Long-Evans rats. Psychopharmacology (Berl). 2009 Dec; 207(2):271-80. PMID: 19756524.
      View in: PubMed
    78. Swerdlow NR, Lelham SA, Sutherland Owens AN, Chang WL, Sassen SD, Talledo JA. Pramipexole effects on startle gating in rats and normal men. Psychopharmacology (Berl). 2009 Sep; 205(4):689-98. PMID: 19506839; PMCID: PMC2718192.
    79. Swerdlow NR, Talledo JA. Effects of the first prepulse on the blink response to a startling noise. Behav Neurosci. 2009 Jun; 123(3):607-13. PMID: 19485567.
      View in: PubMed
    80. Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, Swerdlow NR. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol Biochem Behav. 2009 Aug; 93(2):141-7. PMID: 19426754; PMCID: PMC2720754.
    81. Swerdlow NR, van Bergeijk DP, Bergsma F, Weber E, Talledo J. The effects of memantine on prepulse inhibition. Neuropsychopharmacology. 2009 Jun; 34(7):1854-64. PMID: 19242406; PMCID: PMC2680939.
    82. Talledo JA, Sutherland Owens AN, Schortinghuis T, Swerdlow NR. Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology (Berl). 2009 May; 204(1):165-75. PMID: 19148623; PMCID: PMC2717706.
    83. Weber M, Chang WL, Breier M, Ko D, Swerdlow NR. Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol. 2008 Dec; 19(8):786-95. PMID: 19020413; PMCID: PMC3255557.
    84. Qu Y, Swerdlow NR, Weber M, Stouffer D, Parsons LH. Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies. Pharmacol Biochem Behav. 2008 Oct; 90(4):686-90. PMID: 18579193; PMCID: PMC3250091.
    85. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. PMID: 18701089; PMCID: PMC2653714.
    86. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008 Aug; 199(3):331-88. PMID: 18568339; PMCID: PMC2771731.
    87. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. PMID: 18406578; PMCID: PMC2529172.
    88. Shilling PD, Saint Marie RL, Shoemaker JM, Swerdlow NR. Strain differences in the gating-disruptive effects of apomorphine: relationship to gene expression in nucleus accumbens signaling pathways. Biol Psychiatry. 2008 Apr 15; 63(8):748-58. PMID: 18083141; PMCID: PMC2771724.
    89. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. Advances in endophenotyping schizophrenia. World Psychiatry. 2008 Feb; 7(1):11-8. PMID: 18458787; PMCID: PMC2359727.
    90. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. PMID: 17984393.
      View in: PubMed
    91. Light GA, Swerdlow NR, Braff DL. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci. 2007 Oct; 19(10):1624-32. PMID: 18271737; PMCID: PMC2562660.
    92. Swerdlow NR, Breier M, Mora AB, Ko D, Shoemaker JM. A novel rat strain with enhanced sensitivity to the effects of dopamine agonists on startle gating. Pharmacol Biochem Behav. 2008 Jan; 88(3):280-90. PMID: 17936348; PMCID: PMC2585785.
    93. Swerdlow NR, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. Pharmacol Biochem Behav. 2007 May; 87(1):1-10. PMID: 17475315; PMCID: PMC1995415.
    94. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. PMID: 17346930; PMCID: PMC2039885.
    95. Braff DL, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15; 61(10):1204-7. PMID: 17161386.
      View in: PubMed
    96. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. PMID: 17146007.
      View in: PubMed
    97. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007 Jan; 33(1):69-94. PMID: 17135482; PMCID: PMC2632291.
    98. Swerdlow NR, Blumenthal TD, Sutherland AN, Weber E, Talledo JA. Effects of prepulse intensity, duration, and bandwidth on perceived intensity of startling acoustic stimuli. Biol Psychol. 2007 Mar; 74(3):389-95. PMID: 17118517; PMCID: PMC1992603.
    99. Metzger KL, Shoemaker JM, Kahn JB, Maxwell CR, Liang Y, Tokarczyk J, Kanes SJ, Hans M, Lowman AM, Dan N, Winey KI, Swerdlow NR, Siegel SJ. Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology (Berl). 2007 Feb; 190(2):201-11. PMID: 17119931.
      View in: PubMed
    100. Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, Erenberg G, Jankovic J, Juncos J, Leckman JF, Swerdlow N, Visser-Vandewalle V, Vitek JL. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006 Nov; 21(11):1831-8. PMID: 16991144.
      View in: PubMed
    101. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. PMID: 17035358; PMCID: PMC2632302.
    102. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. PMID: 17023145.
      View in: PubMed
    103. Saint Marie RL, Neary AC, Shoemaker JM, Swerdlow NR. The effects of apomorphine and D-amphetamine on striatal c-Fos expression in Sprague-Dawley and Long Evans rats and their F1 progeny. Brain Res. 2006 Nov 13; 1119(1):203-14. PMID: 16979142.
      View in: PubMed
    104. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff DL. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 01; 60(11):1231-40. PMID: 16893524.
      View in: PubMed
    105. Swerdlow NR, Shoemaker JM, Kuczenski R, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation. Neurosci Lett. 2006 Jul 10; 402(1-2):40-5. PMID: 16644125.
      View in: PubMed
    106. Swerdlow NR, Bongiovanni MJ, Tochen L, Shoemaker JM. Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette Syndrome. Psychopharmacology (Berl). 2006 Jun; 186(2):246-54. PMID: 16583235.
      View in: PubMed
    107. Swerdlow NR, Krupin AS, Bongiovanni MJ, Shoemaker JM, Goins JC, Hammer RP. Heritable differences in the dopaminergic regulation of behavior in rats: relationship to D2-like receptor G-protein function. Neuropsychopharmacology. 2006 Apr; 31(4):721-9. PMID: 16123742; PMCID: PMC1403813.
    108. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. PMID: 16123772; PMCID: PMC1373667.
    109. Swerdlow NR, Talledo J, Sutherland AN, Nagy D, Shoemaker JM. Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology. 2006 Sep; 31(9):2011-21. PMID: 16482083.
      View in: PubMed
    110. Swerdlow NR, Sprock J, Braff DL. Prepulse-elicited motor reactions do not differ between schizophrenia patients and control subjects. Behav Neurosci. 2006 Feb; 120(1):224-7. PMID: 16492135.
      View in: PubMed
    111. Swerdlow NR, Sutherland AN. Preclinical models relevant to Tourette syndrome. Adv Neurol. 2006; 99:69-88. PMID: 16536353.
      View in: PubMed
    112. Swerdlow NR, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Reduced startle gating after D1 blockade: effects of concurrent D2 blockade. Pharmacol Biochem Behav. 2005 Oct; 82(2):293-9. PMID: 16188305; PMCID: PMC1364453.
    113. Hsieh MH, Swerdlow NR, Braff DL. Effects of background and prepulse characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric research. Biol Psychiatry. 2006 Mar 15; 59(6):555-9. PMID: 16169529.
      View in: PubMed
    114. Swerdlow NR. Tourette syndrome: current controversies and the battlefield landscape. Curr Neurol Neurosci Rep. 2005 Sep; 5(5):329-31. PMID: 16131414.
      View in: PubMed
    115. Swerdlow NR, Sutherland AN. Using animal models to develop therapeutics for Tourette Syndrome. Pharmacol Ther. 2005 Dec; 108(3):281-93. PMID: 15970330.
      View in: PubMed
    116. Swerdlow NR, Stephany NL, Talledo J, Light G, Braff DL, Baeyens D, Auerbach PP. Prepulse inhibition of perceived stimulus intensity: paradigm assessment. Biol Psychol. 2005 May; 69(2):133-47. PMID: 15804542.
      View in: PubMed
    117. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 Apr 01; 57(7):817-20. PMID: 15820241.
      View in: PubMed
    118. Swerdlow NR, Talledo JA, Braff DL. Startle modulation in Caucasian-Americans and Asian-Americans: a prelude to genetic/endophenotypic studies across the 'Pacific Rim'. Psychiatr Genet. 2005 Mar; 15(1):61-5. PMID: 15722959.
      View in: PubMed
    119. Swerdlow NR. Much ado about (almost) nothing: response to 'prepulse lost and regained'. Psychopharmacology (Berl). 2005 Jun; 179(4):893-4. PMID: 15645219.
      View in: PubMed
    120. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Sharp R, Minassian A, Auerbach PP. Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. Schizophr Res. 2005 Jan 01; 72(2-3):169-83. PMID: 15560962.
      View in: PubMed
    121. Swerdlow NR, Kuczenski R, Goins JC, Crain SK, Ma LT, Bongiovanni MJ, Shoemaker JM. Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists. Pharmacol Biochem Behav. 2005 Feb; 80(2):203-11. PMID: 15680173.
      View in: PubMed
    122. Harte MK, Powell SB, Reynolds LM, Swerdlow NR, Geyer MA, Reynolds GP. Reduced N-acetylaspartate in the temporal cortex of rats reared in isolation. Biol Psychiatry. 2004 Aug 15; 56(4):296-9. PMID: 15312819.
      View in: PubMed
    123. Swerdlow NR, Talledo J, Shoemaker JM, Codon K, Goins J, Auerbach PP. Weak prepulses inhibit but do not elicit startle in rats and humans. Biol Psychiatry. 2004 Jun 15; 55(12):1195-8. PMID: 15184039.
      View in: PubMed
    124. Swerdlow NR, Shoemaker JM, Crain S, Goins J, Onozuka K, Auerbach PP. Sensitivity to drug effects on prepulse inhibition in inbred and outbred rat strains. Pharmacol Biochem Behav. 2004 Feb; 77(2):291-302. PMID: 14751457.
      View in: PubMed
    125. Swerdlow NR, Shoemaker JM, Noh HR, Ma L, Gaudet I, Munson M, Crain S, Auerbach PP. The ventral hippocampal regulation of prepulse inhibition and its disruption by apomorphine in rats are not mediated via the fornix. Neuroscience. 2004; 123(3):675-85. PMID: 14706779.
      View in: PubMed
    126. Swerdlow NR, Shoemaker JM, Platten A, Pitcher L, Goins J, Auerbach PP. Heritable differences in the dopaminergic regulation of sensorimotor gating. I. Apomorphine effects on startle gating in albino and hooded outbred rat strains and their F1 and N2 progeny. Psychopharmacology (Berl). 2004 Aug; 174(4):441-51. PMID: 15300358.
      View in: PubMed
    127. Swerdlow NR, Shoemaker JM, Auerbach PP, Pitcher L, Goins J, Platten A. Heritable differences in the dopaminergic regulation of sensorimotor gating. II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology (Berl). 2004 Aug; 174(4):452-62. PMID: 15300359.
      View in: PubMed
    128. Swerdlow NR, Shoemaker JM, Platten A, Pitcher L, Goins J, Crain S. Heritable differences in the effects of amphetamine but not DOI on startle gating in albino and hooded outbred rat strains. Pharmacol Biochem Behav. 2003 Apr; 75(1):191-7. PMID: 12759127.
      View in: PubMed
    129. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Sharp R, Auerbach PP. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl). 2003 Sep; 169(3-4):314-20. PMID: 12610717.
      View in: PubMed
    130. Shoemaker JM, Pitcher L, Noh HR, Swerdlow NR. Quetiapine produces a prolonged reversal of the sensorimotor gating-disruptive effects of basolateral amygdala lesions in rats. Behav Neurosci. 2003 Feb; 117(1):136-43. PMID: 12619916.
      View in: PubMed
    131. Swerdlow NR, Platten A, Hanlon FM, Martinez ZA, Printz MP, Auerbach P. Sensitivity to sensorimotor gating-disruptive effects of apomorphine in two outbred parental rat strains and their F1 and N2 progeny. Neuropsychopharmacology. 2003 Feb; 28(2):226-34. PMID: 12589375.
      View in: PubMed
    132. Swerdlow NR, Wasserman LC, Talledo JA, Casas R, Bruins P, Stephany NL. Prestimulus modification of the startle reflex: relationship to personality and physiological markers of dopamine function. Biol Psychol. 2003 Jan; 62(1):17-26. PMID: 12505765.
      View in: PubMed
    133. Swerdlow NR, Pitcher L, Noh HR, Shoemaker JM. Startle gating in rats is disrupted by chemical inactivation but not D2 stimulation of the dorsomedial thalamus. Brain Res. 2002 Oct 25; 953(1-2):246-54. PMID: 12384258.
      View in: PubMed
    134. Swerdlow NR, Stephany N, Wasserman LC, Talledo J, Shoemaker J, Auerbach PP. Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology. 2003 Apr; 28(4):640-50. PMID: 12655308.
      View in: PubMed
    135. Powell SB, Swerdlow NR, Pitcher LK, Geyer MA. Isolation rearing-induced deficits in prepulse inhibition and locomotor habituation are not potentiated by water deprivation. Physiol Behav. 2002 Sep; 77(1):55-64. PMID: 12213502.
      View in: PubMed
    136. Swerdlow NR, Stephany N, Shoemaker JM, Ross L, Wasserman LC, Talledo J, Auerbach PP. Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons. Psychopharmacology (Berl). 2002 Oct; 164(1):82-92. PMID: 12373422.
      View in: PubMed
    137. Swerdlow NR, Shoemaker JM, Stephany N, Wasserman L, Ro HJ, Geyer MA. Prestimulus effects on startle magnitude: sensory or motor? Behav Neurosci. 2002 Aug; 116(4):672-81. PMID: 12148934.
      View in: PubMed
    138. Swerdlow NR, Shoemaker JM, Pitcher L, Platten A, Kuczenski R, Eleey CC, Auerbach P. Genetic differences in startle gating-disruptive effects of apomorphine: evidence for central mediation. Behav Neurosci. 2002 Aug; 116(4):682-90. PMID: 12148935.
      View in: PubMed
    139. Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, Cadenhead K, Auerbach PP. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl). 2002 May; 161(2):189-201. PMID: 11981599.
      View in: PubMed
    140. Martinez ZA, Platten A, Pollack E, Shoemaker J, Ro H, Pitcher L, Geyer MA, Swerdlow NR. "Typical" but not "atypical" antipsychotic effects on startle gating deficits in prepubertal rats. Psychopharmacology (Berl). 2002 Apr; 161(1):38-46. PMID: 11967629.
      View in: PubMed
    141. Swerdlow NR, Platten A, Shoemaker J, Pitcher L, Auerbach P. Effects of pergolide on sensorimotor gating of the startle reflex in rats. Psychopharmacology (Berl). 2001 Nov; 158(3):230-40. PMID: 11713612.
      View in: PubMed
    142. Swerdlow NR, Platten A, Kim YK, Gaudet I, Shoemaker J, Pitcher L, Auerbach P. Sensitivity to the dopaminergic regulation of prepulse inhibition in rats: evidence for genetic, but not environmental determinants. Pharmacol Biochem Behav. 2001 Oct-Nov; 70(2-3):219-26. PMID: 11701191.
      View in: PubMed
    143. Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl). 2001 Jul; 156(2-3):194-215. PMID: 11549223.
      View in: PubMed
    144. Swerdlow NR. Obsessive-compulsive disorder and tic syndromes. Med Clin North Am. 2001 May; 85(3):735-55. PMID: 11349482.
      View in: PubMed
    145. Swerdlow NR, Halim N, Hanlon FM, Platten A, Auerbach PP. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less. Brain Res Bull. 2001 May 01; 55(1):71-7. PMID: 11427340.
      View in: PubMed
    146. Swerdlow NR, Hanlon FM, Henning L, Kim YK, Gaudet I, Halim ND. Regulation of sensorimotor gating in rats by hippocampal NMDA: anatomical localization. Brain Res. 2001 Apr 20; 898(2):195-203. PMID: 11306005.
      View in: PubMed
    147. Swerdlow NR, Eastvold A, Uyan KM, Ploum Y, Cadenhead K. Matching strategies for drug studies of prepulse inhibition in humans. Behav Pharmacol. 2001 Feb; 12(1):45-52. PMID: 11270511.
      View in: PubMed
    148. Swerdlow NR, Eastvold A, Gerbranda T, Uyan KM, Hartman P, Doan Q, Auerbach P. Effects of caffeine on sensorimotor gating of the startle reflex in normal control subjects: impact of caffeine intake and withdrawal. Psychopharmacology (Berl). 2000 Sep; 151(4):368-78. PMID: 11026744.
      View in: PubMed
    149. Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol. 2000 Jun; 11(3-4):185-204. PMID: 11103873.
      View in: PubMed
    150. Swerdlow NR, Martinez ZA, Hanlon FM, Platten A, Farid M, Auerbach P, Braff DL, Geyer MA. Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci. 2000 Jun 01; 20(11):4325-36. PMID: 10818168.
      View in: PubMed
    151. Swerdlow NR, Taaid N, Halim N, Randolph E, Kim YK, Auerbach P. Hippocampal lesions enhance startle gating-disruptive effects of apomorphine in rats: a parametric assessment. Neuroscience. 2000; 96(3):523-36. PMID: 10717433.
      View in: PubMed
    152. Swerdlow NR, Geyer MA, Hartman PL, Sprock J, Auerbach PP, Cadenhead K, Perry W, Braff DL. Sex differences in sensorimotor gating of the human startle reflex: all smoke? Psychopharmacology (Berl). 1999 Sep; 146(2):228-32. PMID: 10525760.
      View in: PubMed
    153. Doan QT, Swerdlow NR. Preliminary findings with a new Vietnamese Stroop test. Percept Mot Skills. 1999 Aug; 89(1):173-82. PMID: 10544412.
      View in: PubMed
    154. Swerdlow NR, Braff DL, Geyer MA. Cross-species studies of sensorimotor gating of the startle reflex. Ann N Y Acad Sci. 1999 Jun 29; 877:202-16. PMID: 10415651.
      View in: PubMed
    155. Swerdlow NR. What role models? Commentary on Robbins' homology in behavioural pharmacology: an approach to animal models of human cognition. Behav Pharmacol. 1998 Nov; 9(7):529-31. PMID: 9862078.
      View in: PubMed
    156. Swerdlow NR, Taaid N, Oostwegel JL, Randolph E, Geyer MA. Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav Pharmacol. 1998 Sep; 9(5-6):389-96. PMID: 9832924.
      View in: PubMed
    157. Swerdlow NR, Braff DL, Hartston H, Perry W, Geyer MA. Latent inhibition in schizophrenia. Schizophr Res. 1996 May; 20(1-2):91-103. PMID: 8794497.
      View in: PubMed
    158. Swerdlow NR, Koob GF.Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behavioral and Brain Sciences. 1987; 10:197-245.
    Neal's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _